| Literature DB >> 21126704 |
Tiberiu Hershcovici1, Ronnie Fass.
Abstract
Patients with gastro-esophageal reflux disease (GERD) who are not responding to proton pump inhibitors (PPIs) given once daily are very common. These therapy-resistant patients have become the new face of GERD in clinical practice in the last decade. Upper endoscopy appears to have a limited diagnostic value. In contrast, esophageal impedance with pH testing on therapy appears to provide the most insightful information about the subsequent management of these patients. Commonly, doubling the PPI dose or switching to another PPI will be offered to patients who failed PPI once daily. Failure of such therapeutic strategies is commonly followed by assessment for weakly or residual acidic reflux. There is growing information about the potential value of compounds that can reduce transient lower esophageal sphincter relaxation rate. Esophageal pain modulators are commonly offered to patients with functional heartburn although supportive clinical studies are still missing. Published by Elsevier Ltd.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21126704 DOI: 10.1016/j.bpg.2010.10.004
Source DB: PubMed Journal: Best Pract Res Clin Gastroenterol ISSN: 1521-6918 Impact factor: 3.043